Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two small molecule drugs, frusemide (also known as furosemide) and indomethacin. Frusemide is a loop diuretic that inhibits the sodium-potassium-chloride cotransporter in the thick ascending limb of the loop of Henle, leading to increased excretion of sodium, chloride, and water. Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin synthesis and exerting anti-inflammatory, analgesic, and antipyretic effects. When used together, indomethacin can blunt or reduce the natriuretic (sodium-excreting) and antihypertensive effects of frusemide by inhibiting renal prostaglandin synthesis[1][2][6]. This interaction may be clinically significant in conditions such as heart failure or when both drugs are required for specific indications like patent ductus arteriosus closure in neonates[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on frusemide + indomethacin.